La Jolla Pharmaceutical (LJPC) - Get Report shares were up 50% in premarket trading Monday after the company announced positive results from a phase 3 trial of its hypotension treatment. 

An independent data safety monitoring board recommended the study continue after the company said tests showed a "highly statistically significant" target blood pressure response.